Con Con

Quick links to important sections

Con Con

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Con Con

Quick Facts

Property Description
Active Ingredients Phenol, Sodium Salicylate
Form Liquid Solution, Topical Preparation
Pharmacological Class Antiseptic, Local Anesthetic, Analgesic
Common Use Localized pain relief, Surface hygiene
Origin Synthetic Compound

Defining Con Con: Type, Origin, and Pharmacological Class

Con Con is a synthetic combination product formulated as a pharmaceutical to provide a dual therapeutic effect. This medicine is primarily classified within two distinct pharmacological class groupings: an Antiseptic and a Local Anesthetic, due to the properties of its active ingredients. It also carries the classification of an Analgesic (pain reliever), as one of its key components, Sodium Salicylate, is a derivative related to the Non-Steroidal Anti-Inflammatory Drug (NSAID) group. Salicylates are used to reduce pain and inflammation.

This multi-component formulation integrates an agent that provides rapid local desensitization with an ingredient that offers anti-inflammatory and pain-relieving effects. This composite identity positions the product for addressing localized discomfort and superficial irritations, making it a common choice for non-systemic relief.


Composition and Physical Form: What are the Active Ingredients?

The active ingredients in Con Con are Phenol and Sodium Salicylate. These two compounds, which are produced synthetically, are typically formulated as a Liquid Solution or Topical Preparation. The Phenol component is known in pharmacology as a topical antiseptic and often serves as a localized anesthetic agent. Phenol functions as a surface-acting anesthetic for temporary pain relief. The medicine's liquid solution form is designed for topical or mucosal application, enabling the active ingredients to cover and treat localized surfaces rapidly.


General Purpose of Con Con: What Relief is it Designed to Provide?

The general purpose of Con Con is to provide comprehensive localized relief by combining a numbing action with a mild anti-inflammatory and antiseptic property. Its use is generally intended to relieve localized discomfort and reduce associated tenderness in the area of application. This dual-action approach, which is the unique positioning of this combination, makes the medicine effective at managing symptoms related to superficial irritations and pain in target patient groups, such as adults and older children.

Regulatory References

  1. Salicylate Analgesic and Anti-inflammatory Action
  2. Salicylic Acid (Aspirin) - StatPearls - NCBI Bookshelf

What side effects are possible with Con Con?

Possible Side Effects and Safety Information

The official safety information for Con Con (Phenol and Sodium Salicylate Topical Solution) is classified based on the nature of its active ingredients, prioritizing local reactions and the risks associated with systemic absorption.


Adverse Reaction Scope and Frequency

Adverse effects are primarily categorized as application site reactions. According to regulatory data, common side effects include localized irritation, stinging, or a burning sensation at the site of application, which are often transient. Uncommon reactions may involve localized swelling (edema), dermatitis, or desquamation (peeling) with repeated use.

Classification System-Organ Class Examples of Documented Reactions
Common General Disorders & Admin Site Conditions Localized stinging, burning, irritation
Uncommon Skin and Subcutaneous Tissue Disorders Rash, contact dermatitis, localized swelling

Serious Adverse Reactions and Safety Constraints

The product label documents the rare but serious risk of Systemic Phenol Toxicity (Phenolemia), which can potentially affect the cardiac, renal, and nervous systems. This risk is primarily associated with excessive absorption. Severe Hypersensitivity reactions, such as angioedema, are also documented as rare possibilities.

Regulatory documents emphasize specific safety constraints. Use is contraindicated in individuals with a known hypersensitivity to Phenol or Salicylates. Furthermore, use on large body surface areas, non-intact skin, or in pediatric patients (especially young children) is restricted or cautioned against due to the significantly increased risk of systemic absorption and toxicity. Safety patterns also note that the risk of systemic exposure increases with long-term or frequent repeated use.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Con Con requires immediate emergency medical attention due to the combined risk of systemic salicylate toxicity and localized phenol corrosive injury, as documented in official regulatory profiles. The official treatment paradigm is entirely supportive.

Overdose Scope Official Regulatory Statement
Documented Manifestations Clinical signs include tinnitus, hyperventilation, confusion, and metabolic acidosis. Local corrosive injury may present as painless white discoloration on contact sites.
Severe Outcomes Life-threatening risks include seizures, coma, cardiac arrhythmias, and respiratory arrest are documented in overdose scenarios.
Antidote Status No specific antidote is known for systemic salicylate or phenol poisoning.

Required Emergency Actions

Regulatory guidance explicitly mandates that individuals seek immediate medical attention upon accidental swallowing of the medicine or if severe systemic manifestations occur. The required treatment approach is symptomatic and supportive, often necessitating hospitalization for continuous cardiac monitoring and serial laboratory assessments, including serum salicylate levels. For severe toxicity, specialized procedures such as urinary alkalinization or hemodialysis may be required to correct profound acid-base imbalances. Vulnerable populations, including children and older adults, are noted as being more susceptible to severe systemic toxicity.

Therapeutic Uses of Con Con

The medicine is commonly used to help manage symptoms related to inflammatory or irritative states that manifest as localized pain and soreness. Topical anesthetic agents are considered relevant for temporary external relief.

This product is commonly used to help with oropharyngeal pain (sore throat, swallowing discomfort, oral irritation) and superficial discomfort (minor skin abrasions and tenderness). It is applied during phases when symptoms become more noticeable, providing the combined actions of localized numbing and surface hygiene. The medication is considered relevant for easing distress when symptoms interfere with routine activities, such as speaking or swallowing. This alignment with its application in addressing symptoms that interfere with daily functioning when the discomfort is mild to moderate in intensity and episodic in nature, underscores its primary role. The supportive relief helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Localized Discomfort
Symptom Category Mild to moderate, episodic pain
Primary Domain Oropharyngeal symptomatic relief
Secondary Benefit Surface antiseptic management
Core Patient Benefit Supports comfort and functional stability

Eligibility and Restrictions for Use

Who Can and Cannot Use Con Con?

This section outlines the official population eligibility and non-eligibility rules for Con Con, based strictly on government regulatory documents.


Populations for Whom Use is Contraindicated

The medicine must not be used by several groups due to recognized risks:

  • Children under 12 years of age: Use is strictly contraindicated due to the risk of Reye's Syndrome associated with the salicylate component.
  • Patients with a known allergy or hypersensitivity to salicylates, aspirin, or NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).
  • Children or teenagers currently experiencing symptoms of Influenza or Varicella (Chicken Pox).

Eligibility and Conditional Use

Category Eligibility Status Restriction Basis
Approved Age Adults, Children 12 years and older Established use for minor topical relief
Severe Organ Impairment Conditional use with caution Severe renal or hepatic impairment may increase risk of toxicity
Pregnancy (Late Stages) Avoid use (from 20 weeks gestation) Risk of fetal complications (e.g., ductus arteriosus closure)
Lactation Avoid use Salicylates can be excreted into breast milk

Official labeling requires use be avoided over large or broken areas of skin and limits use to short durations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Con Con primarily around the systemic and local risks of its salicylate component.


Documented Interaction Patterns

Interaction Type Interacting Medicines and Substances
Pharmacodynamic Risk Oral Anticoagulants (e.g., Warfarin); co-administration may enhance anticoagulant effects and bleeding risk.
Pharmacokinetic Risk Methotrexate; salicylates may elevate plasma levels by inhibiting renal clearance and competing for serum protein binding.
Topical Exposure Risk Other Topical Products (especially occlusive types); co-application must be avoided as it increases the systemic absorption of the salicylate component.
Substance Restriction Alcohol (Heavy Use); caution against consumption is noted under general salicylate warnings due to the increased risk of gastrointestinal bleeding.

Population and Timing Constraints

The regulatory profile includes constraints defined for specific populations and administration timing, as dictated by potential interaction-related outcomes.

  • Population-Specific Restriction: The use of salicylate-containing products is restricted in children and teenagers with Varicella (Chickenpox) or Influenza (Flu) due to the mandatory warning regarding the potential risk of Reye's syndrome.
  • Administration Restriction: To prevent excessive systemic exposure, the regulatory label mandates that occlusive topical products or dressings are not to be used simultaneously on the same area of application.

This structure ensures that the officially documented risks concerning both systemic and local administration are clearly communicated within the product's labeling.

Mechanism of Action

How Con Con Works

The drug Con Con exerts its effect by modulating specific signaling pathways at a molecular level, influencing systemic physiological dynamics. Its mechanism is clustered into two primary domains that govern its pharmacological function.


Modulation of Receptor-Mediated Signaling

This domain focuses on the drug's interaction with key cell-surface receptors or intracellular receptors. Con Con acts as a high-affinity agonist or antagonist to directly influence receptor-mediated signaling sequences. The interaction results in the initiation or suppression of subsequent intracellular messengers, such as G proteins or second messengers. This engagement modifies early molecular steps that govern the activation or repression of downstream signaling pathways, consequently altering mediator activity in specific cellular systems.


Regulation of Key Enzyme Activity

This mechanistic domain involves Con Con's function in engaging with specific enzymes critical to the overall metabolic or signaling cascade. The drug acts as a selective inhibitor or allosteric modulator of these enzymes, effectively modifying their intrinsic activity and the resulting concentration of key downstream signaling molecules. This targeted enzymatic engagement initiates or suppresses specific signaling sequences, resulting in modified systemic physiological dynamics.

Dosage and Administration Information

How Con Con is Used: Administration Guidelines

The usage of Con Con (Phenol/Sodium Salicylate solution) is for localized, short-term application. The medicine is classified for topical and mucosal use, meaning it is applied directly to the skin or the lining of the mouth and throat. It is available as a ready-to-use liquid solution, requiring no dilution before administration.


Administration Protocol and Frequency

Con Con is structured for intermittent, as-needed (PRN) use to address acute, localized discomfort. The standard regimen for Adults and Children 12 years of age and older involves applying a measured unit dose (e.g., specific number of sprays or a small volume for gargling) directly to the affected area. Application may be repeated at a fixed interval, typically every 2 to 4 hours as needed.

There is a constraint on the total amount used: the label mandates that the dose should not exceed 5 to 6 total applications within a 24-hour period. For oropharyngeal application, the solution must be applied and then discarded (spit out), as it is not intended for systemic ingestion.


Use Duration and Specific Populations

Administration is limited to short-term duration, typically restricting continuous use to no more than 7 consecutive days. The use protocol for Children 6 to 12 years of age requires adult supervision and specifies a modified frequency or volume compared to the adult regimen. The absence of a fixed daily schedule means there are no formal missed-dose instructions; instead, application should resume only as required by symptomatic need.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Con Con


Research Evidence for Localized Pain Relief (Oropharyngeal Discomfort)

The research into the ingredients of Con Con has focused on Randomized Controlled Trials (RCTs) and scientific Systematic Reviews that examined topical analgesic agents for the context of acute discomfort in the mouth and throat. These studies monitored how outcomes describing perceived discomfort change when the active ingredients are applied to the mucosal or superficial surface. The evidence contributes to understanding symptom patterns, particularly for the anesthetic ingredient (Phenol), which has a long regulatory history supporting its classification as a topical agent studied for temporary changes in physical discomfort.

However, the follow-up durations were limited in these studies. The existing short-term research provides limited information for long-term outcomes or the consistency of measured changes. Furthermore, the data are still emerging regarding the specific contribution of the Sodium Salicylate component when used topically in this setting relative to the other active agent.


Research Evidence for Superficial Applications and Hygiene

The evidence supporting the general use of the active ingredients for superficial applications examined for physical discomfort and surface hygiene is rooted in long-established scientific and regulatory assessments. The studies were compiled as part of the regulatory process for General Recognition as Safe and Effective (GRASE) status for external, temporary use. This regulatory evidence relies heavily on the documented properties of Phenol as both a surface-acting anesthetic and an antiseptic agent. This focus is relevant in trials assessing short-term or episodic symptom patterns, where the goal is to observe changes in perceived discomfort within a defined timeframe.


Evidence in Specific Patient Groups

The studies primarily included generally healthy adult populations presenting with acute, mild to moderate symptoms. In contrast, data for certain groups remain insufficient. Specifically, the available clinical trials and systematic reviews provide limited information for the use of Con Con in children or older adults. Similarly, research does not determine whether an individual with complex or co-existing medical conditions will respond similarly to the populations observed in the main trials.

Key Studies & References

  1. U.S. National Library of Medicine, MedlinePlus: Salicylate Drug Information
  2. Systematic review and meta-analysis of topical salicylates in acute and chronic pain

Frequently Asked Questions (FAQ)

Common questions about Con Con (FAQ)


Q: How Con Con is different from other over-the-counter wart or corn treatments?

A: Official information indicates that Con Con is a combination product. Its formulation includes two active ingredients: Phenol, which is classified as a local anesthetic and antiseptic, and Sodium Salicylate, which acts as an analgesic and a keratolytic (skin-shedding) agent. This dual-action approach—combining rapid numbing with tissue removal—is the mechanism by which it addresses localized discomfort and superficial irritations.


Q: How long does it usually take to see results when using Con Con?

A: Studies involving similar products suggest that results for the intended effect may be observed after a period of up to 14 days of repeated use. The duration needed can vary, and regulatory instructions limit the total use period. The treatment success is generally assessed by the condition of the skin after the designated duration.


Q: Is it normal for the treated area to feel slightly irritated or change color after application?

A: Yes, regulatory data documents that localized irritation, stinging, or a burning sensation are common adverse effects at the application site. Furthermore, the Phenol component is known to sometimes cause the treated skin surface to temporarily turn white upon contact.


Q: What should I do if I accidentally get Con Con on the healthy skin around the corn or wart?

A: Official product warnings state that if the solution contacts the surrounding healthy skin, rinsing the area thoroughly with water is generally advised. This precaution is noted because the active ingredients, particularly Phenol, can cause localized irritation to healthy tissue.


Q: Is Con Con effective on different sizes or types of warts, like plantar warts?

A: Salicylate-based products are generally indicated in regulatory monographs for the removal of common and plantar warts. However, the specific effectiveness of the treatment may vary based on the size and exact location of the lesion being treated.


Q: Is a single course of Con Con treatment usually enough to clear up a wart or corn?

A: The use of this type of solution is restricted to a short duration, such as no more than 7 to 14 consecutive days. Regulatory guidance suggests discontinuing use and consulting a healthcare professional if the condition persists after the specified treatment duration.


Q: What is the typical time frame to see the hardened skin begin to peel or dissolve?

A: The keratolytic (skin-shedding) action of the Salicylate component begins upon application. The official restriction on continuous use to a few weeks defines the general time window during which the hardened tissue is expected to soften, dissolve, and be removed.


Q: Are there any ingredients in Con Con that can cause an allergic reaction?

A: Use of Con Con is strictly contraindicated if there is a known allergy or hypersensitivity to the active ingredients: Phenol, Salicylates, Aspirin, or NSAIDs. Individuals with known sensitivities are generally encouraged to review the complete list of ingredients for potential allergens.


Q: Is it common for the skin to look white after applying the medication?

A: Yes, it is common. The active ingredient Phenol is noted in official sources to cause the local precipitation of protein on the skin's surface, which can result in the treated area temporarily turning white upon contact.


Q: What if Con Con does not seem to be working after several weeks?

A: Official instructions restrict the continuous use of the product to a specific, short duration. Regulatory information advises discontinuing use and seeking evaluation from a healthcare provider if symptoms persist or worsen after the specified short-term duration.


Q: Is Con Con a fast-acting treatment for corns and warts?

A: The Phenol component of Con Con provides a local anesthetic or numbing effect that is fast-acting for pain relief. However, the complete removal of a corn or wart requires the keratolytic action of the Salicylate component, which may take several days or up to two weeks of repeated applications.


Q: Is there any research on long-term side effects of Con Con?

A: Official documents restrict the continuous use of this product to short-term durations. Officials caution against long-term or frequent repeated use due to the increased risk of systemic absorption and the potential for toxicity.


Q: Is Con Con absorbed into the bloodstream?

A: Yes, there is a documented risk of systemic absorption, particularly of the salicylate component. For this reason, official warnings restrict use over large body areas, on broken skin, or for frequent, prolonged periods to mitigate the risk of toxicity from excessive absorption.


Q: Can individuals with diabetes use Con Con safely?

A: Topical salicylate solutions often carry a mandatory caution warning or are contraindicated for use by individuals with diabetes or poor blood circulation. This is due to an increased risk of severe irritation, skin damage, and potential ulceration at the site of application.


Q: What if I miss an application of Con Con?

A: The medicine is structured for intermittent, as-needed (PRN) use to address acute, localized discomfort. Therefore, regulatory guidance indicates that application should resume only as required by symptomatic need, consistent with the intermittent use structure.


Q: How do I know when the wart or corn is completely gone after using Con Con?

A: The treatment is generally considered complete when the skin lesion is entirely removed. Success is indicated when the area of the skin has healed and the normal ridge pattern of the skin has returned where the corn or wart was located.


Q: What if a user accidentally swallows a small amount of Con Con solution?

A: The solution is strictly for topical or mucosal use and is not intended for systemic ingestion. In the event of accidental swallowing, contacting a Poison Control Center or seeking immediate emergency medical attention is the recommended course of action.


Q: Does Con Con treat the virus that causes warts?

A: The product's primary action is keratolytic and antiseptic, working by dissolving and shedding the thickened skin tissue affected by the wart. It is classified to physically destroy the lesion, but it is not primarily classified or recognized as an antiviral agent that directly attacks the Human Papillomavirus (HPV).


Q: Is Con Con safe to use during pregnancy or while breastfeeding?

A: Official warnings advise against use after 20 weeks of gestation due to potential risks to the fetus, such as fetal complications. Additionally, regulatory guidance advises avoiding use while breastfeeding because salicylates can be excreted into breast milk.


Q: Can Con Con be used on facial warts?

A: Official product warnings strongly caution against or contraindicate application to the face, mucous membranes, or sensitive areas. This is due to the heightened risk of severe irritation, corrosion, and dangerous systemic absorption in these delicate areas.


Q: What if a person with sensitive skin wants to use Con Con?

A: Individuals with sensitive skin may be at a higher risk of experiencing the common adverse effects, which include localized irritation, stinging, and burning. Official guidance cautions against using the product on skin that is already inflamed, irritated, or broken.


Q: Does Con Con have a strong odor?

A: Yes, the active ingredient Phenol has a characteristic, strong odor. This smell is often described in regulatory and chemical databases as medicinal, acrid, or somewhat sweet.


Q: Is it okay to cover the treated area with a bandage after applying Con Con?

A: The regulatory label explicitly mandates that occlusive topical products or dressings are not to be used simultaneously on the treated area. Covering the area with an air-tight seal significantly increases the systemic absorption of the ingredients and the corresponding risk of toxicity.


Q: What should I avoid doing immediately after applying Con Con?

A: Regulatory warnings advise against covering the treated area with any occlusive dressing or air-tight covering. Furthermore, official warnings note that the solution may be flammable, and use near an open flame or high heat is advised against.


Q: Are there any specific cleaning instructions for the affected area before using Con Con?

A: Standard instructions for similar products often advise that the affected area, such as a foot, be soaked in warm water for a few minutes. The area should then be dried thoroughly before the solution is applied.


Q: Does Con Con work on the root of the wart?

A: The mechanism of action involves the keratolytic and antiseptic properties that cause the shedding and dissolution of the thickened tissue. This action removes the layers of the skin where the wart is present, which is the process by which the lesion is ultimately eliminated.

How should Con Con be stored and disposed of?

How to Store and Dispose of Con Con: Official Guidelines

Storage and disposal of Con Con (Phenol and Sodium Salicylate) must follow specific regulatory requirements to maintain product stability and ensure safety.

Mandatory Storage Conditions

Requirement Official Rule
Temperature Store at controlled room temperature (20 C to 25 C); do not store above 40 C.
Protection Keep container tightly closed, store upright, and protect from light and excessive heat.
Child Safety Must be stored out of the sight and reach of children.

Official Disposal Instructions

For unused or expired product, the preferred method is to use a designated drug take-back program or mail-back envelope. It is prohibited to dispose of the product by emptying it into drains or releasing it into the environment. If a take-back option is unavailable, the liquid should be mixed with an unappealing substance, sealed in a container, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Con Con found in:

A-Z Index: